State of Geographic Access to Cancer Treatment Trials in the United States: Are Studies Located Where Patients Live?
Most US counties have limited to no trial offerings, a disparity magnified in counties that are nonmetropolitan, with high social vulnerability, and with high cancer mortality. Effort to facilitate diverse site participation is needed to promote equitable access to trials and to ensure patients participating in trials match the characteristics of patients who will receive interventions once approved. Counties with oncology care sites but no trials provide potential expansion areas.
Authors
- Jeffrey M. Peppercorn (ORCID: https://orcid.org/0000-0001-7138-6404)
- Suanna S. Bruinooge (ORCID: https://orcid.org/0000-0002-9936-2719)
- Ishwaria M. Subbiah (ORCID: https://orcid.org/0000-0002-0758-7911)
- M. Kelsey Kirkwood (ORCID: https://orcid.org/0000-0002-6439-4964)
- Laura A. Levit (ORCID: https://orcid.org/0000-0001-9136-4229)
- David Michael Waterhouse (ORCID: https://orcid.org/0000-0001-5589-9939)
- Dominique C. Hinshaw (ORCID: https://orcid.org/0000-0002-2052-9484)
- Caroline Schenkel (ORCID: https://orcid.org/0000-0002-3613-8509)
Institutions
- American Society of Clinical Oncology (US)
- Sarah Cannon Research Institute (GB)
- Massachusetts General Hospital (US)
- The US Oncology Network (US)
- Oncology Hematology Care (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1200/op.24.00261
- Citations
- 21
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 11.40
Funders
- American Society of Clinical Oncology